What should PT-141 HPLC testing show before an Australian research order?
PT-141 HPLC testing should show a named reversed-phase method, a main peak assigned to bremelanotide, and the area share of that peak. The record is limited to chromatographic and mass-spectral attributes printed on the file. Literature indexes the same compound as PT-141 and as bremelanotide (PMID:15134289; PMID:34436837). Those records are nomenclature anchors, not chromatographic specifications. The header should carry both names, the lot number, and a sequence or formula. The structure used for that check is a cyclic lactam heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, formula C50H68N14O10, average mass near 1025 Da. Ring closure between aspartate and lysine eliminates water, so a linear precursor is about 18 Da heavier and is a different substance. The C-terminus is a carboxylic acid. A separately catalogued cyclic amide differs by about 1 Da. A mass written only as about 1025 can hide that difference. Intact mass should therefore travel with the chromatogram: charge state, measured m/z, theoretical m/z, and the tolerance applied. Using a monoisotopic mass near 1024.5 Da, the doubly charged ion lies near m/z 513.3 and the triply charged ion near m/z 342.5, before adducts. Label any adduct that is present. Recalculate the expected m/z from the formula printed on the file. Retention time supports identity only inside a stated window against a qualified reference run on the same method. For Australian stock, the lot on that header should be the lot named on the tracked dispatch record. PMID:31429064 is retained as a literature identifier for the name string. It does not list column dimensions, gradient time points, detection wavelength, or a warehouse lot. Those fields have to come from the certificate that travels with the dispatched container.
Which method fields make a PT-141 HPLC testing file comparable?
A purity percentage is comparable only when the method is fully stated. The file should list column chemistry, particle size, length and internal diameter, mobile-phase composition, gradient timetable, flow rate, column temperature, detection wavelength, bandwidth, diluent, prepared concentration, load volume, and the data-system method identifier. Without those fields, two Australian listings that both print a high-purity figure may have been measured on gradients that move related substances differently. Reversed-phase C18, or a similar bonded phase, is a common choice for this aromatic peptide. Trifluoroacetic acid is a strong ion-pair reagent and often sharpens ultraviolet peaks. Formic acid is milder and usually preferred when the same peak is sent to electrospray mass spectrometry. A file may use both, but it must identify which method produced the purity figure and which produced the mass. Wavelength defines the purity claim. Near 214 nm the peptide bond dominates, so most peptide-related species contribute. Near 280 nm tryptophan and phenylalanine dominate, so a non-aromatic deletion can look smaller than it is. The report should name the channel used for area percent and, where available, show the second channel. Sample-preparation notes belong in the same table: vessel material, diluent, mixing time, any filtration, and the interval before the run. Adsorption to glass or plastic can lower an assay without changing area-percent purity. These notes describe chromatographic handling only. System suitability closes the method. Expect a blank at the main-peak retention time, resolution from the nearest named related substance, a tailing factor, and signal-to-noise at the reporting threshold. If those checks are absent, the chromatogram is not a complete PT-141 HPLC testing file, however clean the drawn peak appears. Record the void time or hold-up marker if the laboratory uses it to calculate retention factors. A retention time quoted in minutes is not portable across flow rates unless flow, column volume, and gradient shape are also printed. When those values differ between two Australian files, the area-percent results describe different separations and should be listed as method-specific observations rather than as a single ranked purity. A standardised system-suitability block makes two lots comparable even when they were acquired weeks apart on the same nominal column chemistry.
How are related-substance peaks read on a bremelanotide peak table?
The headline purity figure is only as good as the peak table behind it. Each row needs retention time, relative retention time versus the main peak, area, area percent, a label (main peak, specified related substance, or unidentified), and the limit if a limit is claimed. The purity statement should reconcile with 100 minus the summed related-substance percentages, after any documented exclusion of the solvent front or system peaks. If the arithmetic does not close, integration events are missing and the percentage should not be compared across suppliers. Failed lactam closure leaves a linear species about 18 Da heavier, because ring closure eliminates water. Loss of the N-acetyl group shifts mass by about 42 Da. Tryptophan oxidation adds about 16 Da and can change the 280 nm response relative to 214 nm. Deletion and insertion sequences move both mass and retention. Inversion at D-phenylalanine keeps the mass unchanged, so intact mass will not detect a co-eluting diastereomer. Stereochemical control needs a method shown to resolve that pair, or another orthogonal measurement stated on the file. Relative retention time is meaningless without the method identifier. A peak at relative retention 0.92 on one column is not the same observation on another gradient. Reporting thresholds also change the percentage. Integrating from 0.5 percent will look cleaner than integrating from 0.1 percent on the same vial. The threshold, the disregard limit, and the solvent-exclusion rule must be printed. A method should not be called stability-indicating unless specificity for lactam hydrolysis, tryptophan oxidation, and aspartate rearrangement has been documented. Unidentified peaks above the identification threshold should remain visible in the table rather than being collapsed into the main-peak area. The peak table should be organised by relative retention time so an auditor can see whether late-eluting material was integrated or cut off by the run time. Forced baseline events, tangent skims, and manually dropped perpendiculars should be named in the processing notes, because each event can move area percent without a change in the vial.
When is ultraviolet peak purity not enough for identity?
Diode-array software may report a purity angle, a purity threshold, or a spectral match factor across the main peak. A pass means the ultraviolet spectrum looks homogeneous at that signal level. It does not prove a single peptide is present. Related peptides that share the peptide-bond chromophore, and often tryptophan, can co-elute and still pass. A fail can also come from noise, baseline slope, or a mis-set apex, so the index is read with signal-to-noise, not as a standalone verdict. For this sequence, 214 nm homogeneity is a weak screen. A more useful check is the main-peak area ratio of the 214 nm channel to the 280 nm channel, compared with a qualified reference in the same sequence. A co-eluting non-aromatic species shifts that ratio. A co-eluting aromatic analogue may not. Electrospray mass spectrometry of the main peak should show the expected charge-state envelope and no second peptide mass under the ultraviolet peak. The file should state ion mode, mass range, observed m/z, and adducts such as sodium or trifluoroacetate. High-resolution data should include mass error in parts per million against C50H68N14O10. Unit-resolution data should state whether a 1 Da acid-versus-amide difference can actually be resolved. Tandem spectra support sequence assignment only when observed fragments are listed against the cyclic structure. Ring opening precedes many sequence ions, so a bare statement that tandem data confirmed the peak is not evidence. Diastereomers still require chromatographic resolution because they share a mass. A purchase file that binds the chromatogram, the peak-purity trace, and the deconvoluted mass to one sample name is the minimum set a reviewer can audit. Spectral libraries help only when the reference spectrum was acquired on the same detector, bandwidth, and mobile-phase modifiers, because trifluoroacetic acid and formic acid can shift both retention and the apparent ultraviolet baseline under the peak.
Why does area-percent purity differ from net peptide content?
Area-percent purity is a normalisation of integrated peaks on the stated wavelength. It estimates the share of ultraviolet-active material in the main peak. It does not state how much peptide is in the container. Lyophilised solids commonly hold water, residual solvent, and a counter-ion from purification, often trifluoroacetate or acetate. Those components can be nearly invisible at 214 nm. A high area-percent result can therefore sit beside a much lower net peptide content. Net peptide content is a separate assay. It may be quantitative HPLC against a qualified reference, amino-acid analysis, or a nitrogen method, corrected for counter-ion and water. The certificate should name the approach, the reference lot, the replicate count, and the acceptance range. If no content assay was performed, the area-percent figure must not be presented as milligrams of peptide. Laboratories comparing Australian research listings should set documented net peptide content beside gross fill mass, and should treat gross fill mass as a container figure only. This is a documentation check for research procurement. It ranks reported numbers. It does not convert an area-percent result into a weighed peptide quantity. Counter-ion identity sits with the chromatogram. Trifluoroacetate and acetate change solid mass and can disturb the early baseline if residual acid elutes near the solvent front. A fluorine-specific method or ion chromatography can quantify trifluoroacetate; acetate needs its own stated method. Karl Fischer titration quantifies water. Residual solvent, if claimed, needs a headspace gas-chromatography result or an explicit not-tested statement. Specification rows should stay separate: chromatographic purity, specified related substances, unidentified peaks, water, counter-ion, and net peptide content. PT-141 HPLC testing supports the chromatographic rows only and does not certify net content. A worked check is to place chromatographic purity, water, counter-ion, and net peptide content in separate columns of a receiving spreadsheet. If water and counter-ion are marked not tested, the spreadsheet should leave net content blank rather than copy the area-percent figure into that cell. That blank is an analytical gap, not a hidden quantity.
How should the chromatogram be tied to the Australian dispatched lot?
Traceability is the procurement half of the test. The sample name, the sequence-table vessel identifier, the certificate lot number, the chromatogram header, and the label on the dispatched container should be one string. Check that concordance before treating the file as evidence about the material shipped. A cropped figure with no header, or a peak table whose times do not match the figure, breaks the chain. Helpful data-integrity fields are the analysis date, instrument identifier, method version, operator, and reviewer sign-off. Where a supplier holds Australian stock, the lot on the listing should be the lot in the warehouse, and the tracked dispatch record should cite it. Record that lot at receipt and file it with the certificate. A new lot needs a new HPLC file. One chromatogram must not be reused across manufactured lots. Multi-vial orders can share a report only when the pack states that every container was filled from that lot and describes the sampling plan. That is batch documentation. Judge the supplier on the file. Is the method identifier stable across lots? Is net content reported apart from area percent? Literature confirms naming, not vial contents (PMID:15134289; PMID:34436837). Only the lot file links a name to a container. A research certificate characterises the analytical attributes of a research lot: identity assignment, related-substance areas, and the method used to generate them. PMID:31429064 may be filed beside the certificate as a name-index pointer, but it does not contain the lot string, the integration events, or the instrument identifier. Keep the certificate, chromatogram, mass spectrum, and receiving note together so a later audit can reconstruct which file belonged to which container. A useful receiving note also records the file hash or page count, the number of chromatogram figures, and whether the mass spectrum sample name matches the HPLC sample name character for character.
Frequently asked questions
Is PT-141 the same name as bremelanotide on an HPLC certificate?
Indexed literature records this cyclic peptide under the laboratory code PT-141 and the name bremelanotide (PMID:15134289; PMID:34436837). A research certificate should print both strings, plus lot number and formula, so the chromatogram is not matched to a different peptide. Sharing a literature name does not change the research-only status of the lot. The certificate still has to show the lot number, the formula, and the chromatogram that was actually acquired.
Does a single HPLC percentage identify the cyclic peptide?
No. Area percent is the main peak's share of integrated ultraviolet area under a stated method. Identity also needs the formula or sequence, a retention-time window against a qualified reference, and an intact-mass result able to separate the C-terminal acid from an amide analogue about 1 Da away. Diastereomers still need chromatographic resolution because they share a mass. Research use only.
Why can lots with the same area percent differ in net content?
Area percent does not see water, residual solvent, or counter-ions such as trifluoroacetate and acetate, which add mass with little response at 214 nm. Net peptide content is a separate assay corrected for those components. When comparing Australian research listings, set documented net content beside gross fill mass and beside the area-percent figure. The comparison is analytical and concerns reported figures only.
What should match between the container and the HPLC file?
The lot string should agree across the container label, the certificate header, the chromatogram sample name, and the sequence-table vessel identifier. Analysis date, method version, and reviewer sign-off should be readable. A newly manufactured lot needs its own file; one chromatogram should not be reused across lots. Tracked dispatch from Australian stock should cite that same lot identifier.
Does a literature name replace the lot chromatogram?
No. PT-141 HPLC testing characterises chromatographic identity and purity of a research lot. A name that also appears in indexed literature does not transfer method detail or container contents to a catalogue item (PMID:31429064). The auditable record remains the lot-matched chromatogram, peak table, and mass result. Column chemistry, gradient timetable, and integration thresholds still have to be read from that lot file.
Which related substances should a PT-141 peak table be able to show?
Useful named rows include a linear uncyclised species about 18 Da heavier, a des-acetyl species about 42 Da lighter, tryptophan oxidation about 16 Da heavier, deletion sequences, and any diastereomer the method resolves. Unidentified peaks above the stated threshold still need relative retention time and area percent. Print the threshold, or the purity figure cannot be compared between laboratories.
References
- PMID:15134289 — PT-141 Palatin — Curr Opin Investig Drugs — 2004
- PMID:34436837 — Bremelanotide — 2012
- PMID:31429064 — Bremelanotide: First Approval — Drugs — 2019
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
